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A 50-year-old with rapid
neuropsychiatric deterioration and
choreiform movements
Graham Andrew Mackay,1 Stewart Campbell,2 Ravi Jampana,3
Jonathan Cavanagh4
A 50-year-old man presented acutely to
the hospital with behavioural disturbance,
choreiform movements and profound
nihilistic delusions. He reported recent
drug and alcohol abuse, and also apparent
involvement in several recent criminal
activities, for which he felt he should be
punished. He arrived alone at the hospital
after a concerned neighbour had called an
ambulance. His initial level of agitation
prevented formal cognitive testing.
However, he was alert, verbally responsive
and could obey commands. He was
afebrile with normal observations and
normal plasma glucose. Although his
examination was challenging, the only
abnormal neurological findings were bilat-
eral choreiform upper limb movements.
Question 1
What should you do now?
Comments
Obtaining a collateral history is essential
in establishing baseline function in people
presenting with neuropsychiatric distur-
bance. This can help us focus on the
differential diagnoses and plan for inves-
tigation. It can also avoid repeating
previous investigations.
The admitting team contacted his
brother, his next of kin. The patient was
an unemployed ex-builder. One year
earlier, he had consulted a movement
disorder doctor with a high-frequency
tremor and brief involuntary movements.
Investigations at this time included a
normal MR scan of the brain and routine
blood tests, including thyroid function
tests and serum calcium. In the 2 months
before admission, his family had noticed
occasional repetitive conversation.
However, he still lived independently and
attended training courses. His agitation
and disorientation had developed over
the 24 hours before presentation. There
was no family history of dementia or of
involuntary movements.
Question 2
What is the differential diagnosis?
Question 3
What initial investigations would you plan?
Causes of cognitive impairment and
chorea (box 1).
Urine screening for illicit drugs was
negative. The following were normal:
blood film, renal function, serum
calcium, thyroid function tests and serum
C-reactive protein; serum antistreptolysin
O titres were negative. Urinalysis was
normal. MR scan of the brain, including
diffusion-weighted and susceptibility
sequences, showed only minor non-
specific white matter abnormalities. Cere-
bral MR angiography was also normal.
Comments
Before lumbar puncture, he was noted to
have a prolonged activated partial throm-
boplastin time but normal prothrombin
time. This did not correct with vitamin
K, prompting his medical team to look
for the lupus anticoagulant and for serum
antinuclear antibodies. His lumbar punc-
ture showed 20  106red cells/l (0) and
10  106 white cells/l (5) (lymphocytes)
with normal cerebrospinal fluid (CSF)
protein and glucose concentrations.
Oligoclonal band testing was equivocal.
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His serum was positive for antinuclear antibody (1/
640), anti-double-stranded DNA (ELISA) at 840.4 U/
mL (<35) and positive anti-DNA immunophoresis.
He had a prolonged activated partial thromboplastin
time and positive testing for the lupus anticoagulant
(Dilute Russell"s viper venom time (DRWT)). He had
positive anticardiolipin IgG 16.9 U/mL (normal <10),
but normal IgM levels. His serum complement C3
levels were initially low at 0.71 g/l (normal >0.8),
with normal C4 levels.
Question 4
What is the most likely diagnosis?
Question 5
How would you initially treat him?
Comments
We made the presumptive diagnosis of diffuse neuro-
psychiatric lupus. He was originally treated with 5
days of intravenous methylprednisolone, with clear
initial improvement in his agitation and lessening of
his involuntary movements. He scored 54/100 on the
revised Addenbrooke’s Cognitive Assessment (ACE-
R). The rheumatology team started him on tapering
oral corticosteroids, followed by intravenous cyclo-
phosphamide 500 mg weekly for 6 weeks. He did not
improve and, if anything, deteriorated further with
more intrusive depressive thoughts, worsening cogni-
tive function and a return of the chorea. He began
complaining of visual hallucinations of a dog in his
room.
Question 6
How would you manage him now?
Question 7
Are there any other treatment options and how might you
monitor their impact?
Comments
Given his emerging depressive psychotic symptoms,
we arranged for psychiatric evaluation. He was
treated with venlafaxine and then additionally quetia-
pine, with a gradual impact on his depressive
symptoms and resolution of the hallucinations. At this
stage, he had five plasma exchange treatments
without clear effect. An hexamethylpropyleneamine
oxime (HMPOA) single photon emission CT (SPECT)
showed bilateral cortical hypoperfusion, most promi-
nent over the left temporal lobe (figure 1). Given his
static and severely impaired cognitive function, we
started him on intravenous rituximab. He received
four weekly doses of 600 mg, having been screened
for relevant infections (HIV, hepatitis B and C, and
tuberculosis). His cognitive function significantly
improved, the ACE-R score rising to 80/100. Repeat
HMPOA SPECT showed increased perfusion (figure
1). During this time, he also received low-molecular-
weight heparin for 6 weeks, given the associated anti-
phospholipid antibodies although vascular imaging
never showed evidence of thrombosis. He now takes
hydroxychloroquine as maintenance immunosuppres-
sive therapy along with the venlafaxine and
quetiapine. He manages self-care, but 12 months after
initial presentation he still cannot yet live indepen-
dently, requiring some supervision. His depression has
resolved and his personality has returned to normal.
DISCUSSION
Most neuropsychiatric lupus events occur at onset or
within an year of onset (50%–60%).1 The American
College of Rheumatology criteria for classifying
neuropsychiatric lupus is very broad and includes 19
potential neurological and psychiatric syndromes
(table 1), including both central and peripheral
syndromes.2 The spectrum of events varies from
Box 1 Differential diagnosis for rapid cognitive
decline and chorea
" Drug-induced chorea, such as cocaine, amphetamines,
lithium, methylphenidate, benzodiazepines, neuroleptics)
" Basal ganglia lesion
 Stroke (sub-thalamic nucleus)
 Space occupying lesion
" Postinfective, such as herpes simplex virus, Sydenham’s
chorea, paediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections, AIDS
" Thyrotoxicosis
" Systemic lupus erythematosus/antiphospholipid syndrome
" Polycythaemia rubra vera
" Chorea gravidarum
" Autoimmune encephalitis (NMDAr)
" Variant Creutzfeldt-Jakob disease
" Inherited conditions
 Huntington’s disease
 Wilson’s disease
 Neuroacanthocytosis, Macleod’s syndrome
 Neuroferritinopathy/pantothenate kinase-associated
neurodegeneration
 Kufs disease, corticobasal degeneration, dentatorubral-
pallidoluysian atrophy, Lesch-Nyhan syndrome
 Friedreich’s ataxia
 Mitochondrial disorders
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headache, mood disorders and mild cognitive
impairment to severe cases.3 Severe cognitive cases
such as this comprise only 3%–9% of neuropsychi-
atric lupus.1 4 Chorea is the most common movement
disorder and is associated with antiphospholipid anti-
bodies, but occurs in less than 4% of cases.1 3 Severe
neuropsychiatric cases have either focal or diffuse
presentations.5–7 The focal cases have ischaemic,
thrombotic or demyelinating lesions. Our patient had
a diffuse presentation, similar to several previously
described cases. However, these diffuse cases were
variably described as having severe neuropsychiatric
lupus or acute confusional state presentations, making
it difficult to compare the reported cases.
These diffuse cases are most likely immune mediated,
possibly with several autoantibodies, including antiri-
bosomal-P, anti-DNA, antiphospholipid, NMDA NR2
and GABA-B antibodies, supporting this assertion.8 9
Patients with suspected neuropsychiatric lupus
should have an MR scan of brain10 to exclude several
differential diagnoses, including demyelination,
ischaemia or thrombosis. Over half of neuropsychiatric
lupus cases have normal MR brain scans.5 8 Non-
specific white matter abnormalities are common in
systemic lupus erythematosus and in neuropsychiatric
lupus cases, and are non-discriminatory.5 11 Serial MR
brain scans in diffuse neuropsychiatric lupus cases may
show rapidly progressive generalised brain atrophy.12
Lumbar puncture is important to exclude central
nervous system (CNS) infection; it can show an inflam-
matory response but can be normal. Some patients
have positive CSF oligoclonal bands and other CSF
immune biomarkers, such as anti-DNA antibodies,
interleukin-6 and tumour necrosis factor alpha.9
Several studies have shown altered cerebral metabo-
lism in neuropsychiatric lupus. Thus, SPECT scans
may be diagnostically useful in patients with normal
MRI, especially those with a diffuse cognitive presen-
tation (where it is 75%–93% sensitive).1 9 13 SPECT
scans may be used as a biomarker for the immediate
response to immunotherapy,9 14 but do not help in
subsequent monitoring or predicting further neuro-
psychiatric events. 15
Figure 1 Cerebral perfusion single photon emission CT using intravenously injected Tc99m HMPAO. Axial projections. Pretreatment
(top row) and post-treatment (bottom row) scans. As shown in the colour scale to the left, the brighter yellow the colour the greater
the perfusion. Cortical perfusion is generally reduced on the pretreatment scan, but significantly improved after treatment.
Table 1 American College of Rheumatology Neuropsychiatric
Systemic Lupus Erythematosus classification (1999)
Central nervous system Peripheral nervous system
Aseptic meningitis Acute inflammatory
demyelinating polyradiculopathy
Cerebrovascular disease Autonomic disorder
Demyelinating syndrome Mononeuropathy (single/
multiple)
Headache Myasthenia gravis
Movement disorder (chorea)* Cranial neuropathy
Myelopathy Plexopathy
Seizure disorder* Polyneuropathy
Acute confusional state*
Anxiety disorder
Cognitive dysfunction*
Mood disorder*
Psychosis*
*Presentations associated with diffuse neuropsychiatric lupus.
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Patients with psychiatric symptoms should receive
antidepressant and antipsychotic agents.1 Electrocon-
vulsive therapy was effective in three cases with
severe psychosis.16 Patients with cognitive decline
often respond to glucocorticoids and other immuno-
suppressants1, although corticosteroids can aggravate
the psychiatric symptoms. There is evidence for using
cyclophosphamide and plasma exchange (sometimes
synchronised) in refractory cases1 17 and for rituximab
in severe refractory cases.9 13 14 18 Patients with either
a long disease duration or with more than one of the
American College of Rheumatology syndromes
(table 1)13 have a poorer therapeutic prognosis.9
Although several CSF cytokine, chemokine and
growth factors have been used as markers of the
inflammatory process, a more specific biomarker
would greatly improve diagnostic and therapeutic
research into this rare condition.9
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